Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Bayer Yakuhin Sees Cancer Drugs as New Pillar
July 9, 2014
-
BUSINESS MTPC Aspires to Derive 30% of Sales from Offshore Biz
July 8, 2014
-
BUSINESS Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
July 7, 2014
-
BUSINESS Sawai Preparing to File More Products for US Approval: Exec
July 4, 2014
-
REGULATORY MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement
July 4, 2014
-
BUSINESS Meiji Seika Pharma Wants to Make Cancer Drugs, Biologics 4th Biz Pillar
July 3, 2014
-
BUSINESS Pfizer Japan to Diversify Revenue Streams to Maintain Growth in “Post-Lipitor Era”: President
July 2, 2014
-
REGULATORY Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
July 1, 2014
-
BUSINESS Sanofi, Takeda Team Up to Raise Awareness of Diabetes
July 1, 2014
-
BUSINESS Takeda CEO Counters Opposing Shareholders, Says Mr Weber Most Appropriate to Lead Drug Maker
June 30, 2014
-
BUSINESS Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
-
BUSINESS Kyowa Pres. Eyes Excursion into Authorized Generic Territory
June 26, 2014
-
REGULATORY Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
-
ACADEMIA Univ. Says Data Leaks in SIGN Run Afoul of Personal Information Law, Newly Finds Bristol’s Misconduct
June 25, 2014
-
BUSINESS Plavix Grabs Top Spot in FY2013 Domestic Ethical Drug Sales Ranking
June 24, 2014
-
BUSINESS Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
-
REGULATORY First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
-
BUSINESS Takeda Ceases Development of TAK-700 for Prostate Cancer on Lackluster PIII Results
June 20, 2014
-
BUSINESS Japan Vaccine President and Chairman Swap Posts
June 19, 2014
-
REGULATORY LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…